Cassidy Richard J, Indelicato Daniel J, Gibbs Charles P, Scarborough Mark T, Morris Christopher G, Zlotecki Robert A
Departments of *Radiation Oncology ‡Orthopaedics,University of Florida College of Medicine, Gainesville †University of Florida Proton Therapy Institute, Jacksonville, FL.
Am J Clin Oncol. 2016 Dec;39(6):600-603. doi: 10.1097/COC.0000000000000107.
To evaluate outcomes after conservative resection and radiotherapy (RT) for soft-tissue sarcoma (STS) of the distal extremity, with assessment of functional quality of life using the validated Toronto Extremity Salvage Score (TESS) questionnaire and Common Terminology Criteria for Adverse Events (CTCAE), v4.0.
Thirty-three patients with STS involving the hand/wrist (N=18) or foot/ankle (N=15) complex received adjuvant RT with conservative resection and were evaluated for local tumor control, survival, toxicities, and preservation of objective functional ability. Eight patients were treated with preoperative RT (median dose, 50.4 Gy) and 25 with postoperative RT (median dose, 61.8 Gy). Median follow-up was 11.5 years. Functional outcomes were measured using TESS; patients with amputations were excluded from the TESS analysis. Adverse events related to gait, limb edema, skin infection, wound complication, and wound dehiscence were assessed using the CTCAE.
The 5- and 10-year local control rates were both 90%. The 10-year cause-specific, absolute, and distant metastasis-free survival rates were 97%, 87%, and 84%, respectively. Three patients had an amputation for reasons other than local recurrence or treatment complications and underwent amputation for patient preference. One third of the subjects (11/33 patients) were able to complete the TESS questionnaire; scores ranged from 88 to 100 (mean, 98.2). CTCAEv4 acute adverse events occurred in 2 cases: 1 patient had a grade 3 skin infection and 1 had a grade 2 wound complication of dehiscence.
For management of distal extremity STS, the combination of adjuvant RT and conservative surgery achieves excellent local control and overall survival with few adverse events. In addition, through application of the TESS survey instrument, we have demonstrated that this treatment plan achieves robust functional preservation objectively and quantifiably.
评估保守性切除联合放疗(RT)治疗远端肢体软组织肉瘤(STS)后的疗效,使用经过验证的多伦多肢体挽救评分(TESS)问卷和不良事件通用术语标准(CTCAE)v4.0评估功能生活质量。
33例累及手部/腕部(n = 18)或足部/踝部(n = 15)复合体的STS患者接受了辅助放疗联合保守性切除,并对局部肿瘤控制、生存、毒性以及客观功能能力的保留情况进行了评估。8例患者接受术前放疗(中位剂量,50.4 Gy),25例接受术后放疗(中位剂量,61.8 Gy)。中位随访时间为11.5年。使用TESS测量功能结局;截肢患者被排除在TESS分析之外。使用CTCAE评估与步态、肢体水肿、皮肤感染、伤口并发症和伤口裂开相关的不良事件。
5年和10年局部控制率均为90%。10年病因特异性、绝对和无远处转移生存率分别为97%、87%和84%。3例患者因局部复发或治疗并发症以外的原因接受了截肢,因患者意愿接受了截肢。三分之一的受试者(11/33例患者)能够完成TESS问卷;评分范围为88至100(平均,98.2)。CTCAEv4急性不良事件发生2例:1例患者发生3级皮肤感染,1例发生2级伤口裂开并发症。
对于远端肢体STS的治疗,辅助放疗联合保守手术可实现良好的局部控制和总体生存,不良事件较少。此外,通过应用TESS调查工具,我们证明了该治疗方案在客观和定量方面实现了强大的功能保留。